<scp>Post‐COVID</scp>‐19 irritable bowel syndrome

Cooney, Joseph; Poullis, Andrew

doi:10.1111/nmo.14420

Cited by 4 publications

(4 citation statements)

References 6 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SARS-CoV-2 targeted GI cells that expressed ACE2, leading to inflammatory responses and the release of cytokines ( 18 ), thereby impairing the gut barrier function ( 19 ). Research had shown that up to 6 months after acute infection, the presence of SARS-CoV-2 nucleic acid was found in the small intestines of COVID-19 survivors, accompanied by persistent immune activation, hypothesized as the cause of persistent GI symptoms post-COVID-19 ( 20 ). Moreover, the gut microbiota of the COVID-19 patients underwent changes ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

Long-term gastrointestinal symptoms and sleep quality sequelae in adolescents after COVID-19: a retrospective study

Yang,

Wang,

Wang

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

ObjectiveTo evaluate the long-term gastrointestinal (GI) symptoms and sleep quality sequelae in adolescents with COVID-19.MethodsBetween June and July 2023, an online survey was done in Xiaoshan District, Hangzhou City, Zhejiang Province, China, using the GI Symptom Rating Scale (GSRS) and the Pittsburgh Sleep Quality Inventory (PSQI).ResultsGI symptoms in COVID-19 patients increased by 11.86% compared to before infection, while sleep quality decreased by 10.9%. Over time, there was a significant increase in the cumulative incidence rate of GI symptoms and sleep disorders (p < 0.001). Follow-up of COVID-19 positive patients within 6 months of infection showed that GI symptoms and sleep quality began to ease starting from the first month after infection. Further analysis indicated a significant linear relationship between the severity of GI symptoms and sleep quality (R > 0.5, p < 0.001). Moreover, females, older age, and higher education were identified as risk factors influencing the long-term effects of COVID-19.ConclusionSARS-CoV-2 affects GI symptoms and sleep quality in adolescents during both the acute phase and post-infection periods. Over time, these symptoms gradually alleviate. A significant correlation exists between GI symptoms and sleep quality.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term gastrointestinal symptoms and sleep quality sequelae in adolescents after COVID-19: a retrospective study

Yang,

Wang,

Wang

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…As reported by Cooney and Poullis, even though PI-IBS is becoming a global challenge, there are only a few studies and, therefore, limited knowledge [61]. Physicians should be aware that COVID-19 infection may lead to the development of chronic DGBI, such as IBS.…”

Section: Post-covid Irritable Bowel Syndrome Managementmentioning

confidence: 97%

Post-COVID-19 and Irritable Bowel Syndrome: A Literature Review

Paramythiotis,

Karlafti,

Didagelos

et al. 2023

Medicina

View full text Add to dashboard Cite

The emergence of post-COVID-19 syndrome (PCS), a complex and multifactorial condition that follows the acute COVID-19 infection, has raised serious concerns within the global medical community. Concurrently, Irritable Bowel Syndrome (IBS), a widespread chronic gastrointestinal (GI) dysfunction, is considered to be one of the most common disorders of gut–brain interaction (DGBI) that significantly affects the quality of life and social functioning of patients. PCS presents a wide range of symptoms and GI manifestations, including IBS. This review aims to analyze the GI involvement and the prolonged symptoms of COVID-19 infection as part of PCS, in order to explore the potential development of post-infection IBS (PI-IBS) in COVID-19 patients. Irritating factors such as enteric infection, psychosocial conditions, food antigens, and antibiotics may lead to abnormalities in the physiological function of the GI system and could be involved in the development of PI-IBS. Through the presentation of the pathophysiological mechanisms and epidemiological studies that assessed the prevalence of IBS as part of PCS, we attempted to provide a better understanding of the long-term consequences of COVID-19 and the pathogenesis of PI-IBS. Even though PI-IBS is becoming a global challenge, there are only a few studies about it and therefore limited knowledge. Currently, the majority of the existing treatment options are referred to non-COVID-19-associated DGBIs. Forthcoming studies may shed light on the mechanisms of PI-IBS that could be targeted for treatment development.

show abstract

“…SARS-CoV-2 infection, alongside individual susceptibility and host immunity, can even progress to severe and life-threatening pneumonia, which is responsible for increased morbidity and mortality in Coronavirus Disease 2019 (COVID-19) [ 13 ]. Patients with either acute COVID-19 or post-acute COVID Syndrome (PACS) were reported to have gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting [ 14 , 15 ]. Interestingly, patients with PACS at 6 months showed gut microbiome dysbiosis compared with non-COVID-19 controls and patients without PACS, while the development of PACS was not significantly correlated with viral load both in respiratory and stool [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Butyrate Protects against SARS-CoV-2-Induced Tissue Damage in Golden Hamsters

Yu,

Yuan,

Yan

et al. 2023

IJMS

View full text Add to dashboard Cite

Butyrate, produced by gut microbe during dietary fiber fermentation, has anti-inflammatory and antioxidant effects on chronic inflammation diseases, yet it remains to be explored whether butyrate has protective effects against viral infections. Here, we demonstrated that butyrate alleviated tissue injury in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected golden hamsters supplemented with butyrate before and during the infection. Butyrate-treated hamsters showed augmentation of type I interferon (IFN) response and activation of endothelial cells without exaggerated inflammation. In addition, butyrate regulated redox homeostasis by enhancing the activity of superoxide dismutase (SOD) to inhibit excessive apoptotic cell death. Therefore, butyrate exhibited effective prevention against SARS-CoV-2 by upregulating antiviral immune responses and promoting cell survival.

show abstract

Post‐COVID‐19 irritable bowel syndrome

Cited by 4 publications

References 6 publications

Long-term gastrointestinal symptoms and sleep quality sequelae in adolescents after COVID-19: a retrospective study

Long-term gastrointestinal symptoms and sleep quality sequelae in adolescents after COVID-19: a retrospective study

Post-COVID-19 and Irritable Bowel Syndrome: A Literature Review

Butyrate Protects against SARS-CoV-2-Induced Tissue Damage in Golden Hamsters

Contact Info

Product

Resources

About